Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691820 · ClinicalTrials.gov registry record · NA
A Study in Adolescent Females to Explore Cytomegalovirus Infection
A NA study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- NA
- Development phase
- 369
- Enrollment target
NCT01691820: Completed NA study, sponsored by GlaxoSmithKline.
NCT01691820 is a NA study that has completed, run by GlaxoSmithKline. The registered enrollment target is 369 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01691820, a NA study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- NA
- Development phase
- 369 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the incidence of Cytomegalovirus (CMV) secondary infections (re-infections/re-activations) and the incidence of CMV primary infections in adolescent females.
Primary Outcome
This outcome was part of the assessment of occurrence of CMV secondary infections determined in all seropositive subjects. Two-fold and above increases" category = subjects that had two-fold and above increases of anti-CMV Immunoglobulin G (IgG) concentration. "Four-fold and above increases" = subjects that had four-fold and above increases of anti-CMV IgG concentration. The cut-off of the assay = 1.136 ELISA unit (EU)/mL. A seropositive subject is a subject for whom anti-CMV IgG antibodies were
Interventions
- PROCEDURE Blood collection
- PROCEDURE Urine collection
- PROCEDURE Saliva collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2012-10-05 |
| Est. Completion | 2017-04-08 |
| Phase | NA |
What the finished NCT01691820 record still lists
NCT01691820 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which Blood collection is the first listed.
NCT01691820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01691820 about?
NCT01691820 is a clinical study titled "A Study in Adolescent Females to Explore Cytomegalovirus Infection". The purpose of this study is to estimate the incidence of Cytomegalovirus (CMV) secondary infections (re-infections/re-activations) and the incidence of CMV primary infections in adolescent females.
What is the current status of trial NCT01691820?
This trial is currently completed. It is a NA study. The enrollment target is 369 participants. The study started on 2012-10-05. Estimated completion is 2017-04-08.
What interventions are being tested in trial NCT01691820?
The interventions under investigation include: Blood collection (PROCEDURE), Urine collection (PROCEDURE), Saliva collection (PROCEDURE).
Who is sponsoring clinical trial NCT01691820?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01691820's enrollment target sits among peer trials
369 281st of 2000 higher than 1,718 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI